Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics (SYRE) granted inducement equity awards to a new non-executive employee, consisting of options to purchase 2,106 common shares and 745 restricted stock units under its 2018 Equity Inducement Plan.

Rhea-AI Summary

Spyre Therapeutics (SYRE) granted inducement equity awards to a new non-executive employee, consisting of options to purchase 2,106 common shares and 745 restricted stock units under its 2018 Equity Inducement Plan. The awards were approved on September 1, 2026 in line with Nasdaq Listing Rule 5635(c)(4).

The stock options have a 10-year term and an exercise price of $88.50, equal to Spyre’s September 1, 2026 closing share price. Options vest 25% on the first anniversary of the employee’s start date, with the remaining 75% vesting monthly over the next three years, subject to continuous service. RSUs vest in four equal annual installments on specified quarterly vesting dates following the start date, also contingent on continued service.

Market Context

The August 7 inducement-award announcement was followed by a 0.4% 24-hour move. That precedent frame...

Analysis

The August 7 inducement-award announcement was followed by a 0.4% 24-hour move. That precedent frames the new grant as compensation-related news, while the active S-3ASR and recent net selling are risks to monitor.

Key Figures

Stock options: 2,106 shares Restricted stock units: 745 RSUs Approval date: September 1, 2026 +5 more

8 metrics

Stock options 2,106 shares Equity inducement award to one non-executive employee

Restricted stock units 745 RSUs Equity inducement award to one non-executive employee

Approval date September 1, 2026 Date the options and RSUs were approved

Option term 10 years Term of the granted stock options

Exercise price $88.50 Equal to the September 1, 2026 closing price

Initial option vesting 1/4 of shares Vests on the first anniversary of the employee's start date

Monthly option vesting 1/48 of shares Vests monthly thereafter, subject to continuous service

RSU vesting 1/4 of shares annually Vests on each applicable quarterly anniversary date

Historical Context

5 past events · Latest: Aug 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 25	Clinical trial results	Neutral	-12.8%	Mixed rheumatoid arthritis data despite statistically significant low-dose endpoint improvement
Aug 10	Clinical trial launch	Positive	+0.4%	Launched SPY772 and initiated a Phase 2 hidradenitis suppurativa trial
Aug 07	Inducement award grants	Neutral	+0.4%	Granted options and RSUs to four non-executive employees
Aug 04	Quarterly earnings	Positive	-0.6%	Reported second-quarter results and positive Phase 2 clinical progress
Jul 02	Inducement award grants	Neutral	+2.4%	Granted options and RSUs to six non-executive employees

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Inducement-award announcements were followed by positive 24-hour reactions, while the recent clinical-data announcement was followed by a negative reaction.

Key Terms

restricted stock units, equity inducement award, nasdaq listing rule 5635(c)(4)

3 terms

restricted stock units financial

"745 restricted stock units (“RSUs”) to one non-executive employee"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

equity inducement award financial

"as an equity inducement award under the Spyre Therapeutics"

An equity inducement award is a grant of company stock or stock-based rights given to a new employee as a hiring incentive, paid in addition to normal pay and benefit programs. It works like a signing bonus but in company shares, aligning the hire’s interests with shareholders while also increasing the number of outstanding shares; investors watch these awards for their impact on ownership dilution, executive motivation, and reported compensation costs.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 2,106 shares of common stock of Spyre and 745 restricted stock units (“RSUs”) to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on September 1, 2026 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $88.50, the closing price per share of Spyre's common stock as reported by Nasdaq on September 1, 2026. The options granted to the employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employee shall vest as to one-fourth (1/4^th) of the shares subject to the respective RSUs on each anniversary of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, please visit http://spyre.com.

For Investors:
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

FAQ

What inducement equity awards did Spyre Therapeutics (SYRE) grant in September 2026?

Spyre Therapeutics granted a new non-executive employee stock options to purchase 2,106 shares of common stock and 745 RSUs as an equity inducement award. The grants were made under the company’s 2018 Equity Inducement Plan and approved on September 1, 2026.

What are the key terms of the Spyre Therapeutics (SYRE) inducement stock options?

The inducement stock options have a 10-year term and an exercise price of $88.50, equal to Spyre’s September 1, 2026 closing share price. They were granted under the 2018 Equity Inducement Plan and are subject to continuous service-based vesting conditions.

How do the inducement stock options for the new Spyre Therapeutics (SYRE) employee vest?

The options vest as to 25% of the shares on the first anniversary of the employee’s start date. The remaining 75% vests in equal monthly installments (1/48th of the total) thereafter, subject to the employee’s continuous service with Spyre through each vesting date.

What is the vesting schedule for the RSUs granted by Spyre Therapeutics (SYRE) to the new employee?

The 745 RSUs vest in four equal installments of 25% each on successive anniversaries of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date, as long as the employee remains in continuous service through each vesting date.

Under what plan and Nasdaq rule were Spyre Therapeutics (SYRE) inducement awards granted?

The stock options and RSUs were granted under the Spyre Therapeutics 2018 Equity Inducement Plan, as amended. The company states that these awards were material to the employee’s acceptance of employment and were made in accordance with Nasdaq Listing Rule 5635(c)(4).